Back to results
US 6,387,880 B1Granted
Transdermal N-[N-[5-[4-(aminoiminomethly)phenyl]-1-oxopentyl]-L-α-aspartyl]-L-phenylalainine or its esters and their pharmaceutically acceptable salts
AssigneeG.D. Searle & Co.
InventorsLarry P. Feigen, Martin John Griffin
Life of this patent
Estimating the term…
Abstract
The present invention is for pharmaceutical compositions and a method of use for the transdermal delivery of N-[N-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-L-α-aspartyl]-L-phenylalanine or its esters and their pharmaceutically acceptable salts which are useful as platelet aggregation inhibitors.
Claims10
A pharmaceutical composition or transdermal delivery of compounds having formula:
- wherein R can be independently hydrogen or alkyl having 1 to 6 carbon atoms
- or the pharmaceutically acceptable salt comprising:
- a therapeutically effective amount of a compound having the formula
- wherein R can be independently hydrogen or alkyl having 1 to 6 carbon atoms or the pharmaceutically acceptable salt;
- and
- a delivery solvent selected from the group consisting of methanol, ethanol, saline and n-methyl pyrrolidone for delivering a therapeutically effective amount of a compound having the formula
- wherein R can be independently hydrogen or alkyl having 1 to 6 carbon atoms or the pharmaceutically acceptable salt through the skin.
4 more elements
A method of use of a compound having the formula
- wherein R can be independently hydrogen or alkyl having 1 to 6 carbon atoms or the pharmaceutically acceptable salt, and a delivery solvent selected from the group consisting of methanol, ethanol, saline and n-methyl pyrrolidone for preparing a pharmaceutical composition for the transdermal delivery of a compound having the formula
- wherein R can be independently hydrogen or alkyl having 1 to 6 carbon atoms or the pharmaceutically acceptable salt;
- through the skin.
Dependencies are inferred from the claim text.